$SNN

Smith+Nephew (LSE: SN, NYSE: SNN) launched its CARTIHEAL AGILI-C cartilage repair implant in Europe. The implant, made of aragonite, showed superior clinical results in a 5-year study, improving pain relief and functional outcomes. It will be showcased at the ICRS Congress in Portugal. The company plans to expand availability to more countries soon.

Smith & Nephew (LSE:SN, NYSE:SNN) priced a cash tender offer for up to $250M of its 2.032% Senior Notes due 2030. The offer expires today, with a settlement date expected on September 18, 2026. The tender offer consideration is $878.90 per $1,000 principal amount. The company may prorate the offer if oversubscribed.

Smith & Nephew (LSE:SN, NYSE:SNN) offers to buy up to $250m of its 2.032% notes due 2030. The tender is part of debt portfolio management and aims to extend debt maturity. Acceptance is conditional on a concurrent notes offering. Pricing and allocation details are outlined in the offer.

Analysts from UBS, Truist, BTIG, and Barclays updated ratings and price targets for Medtronic (MDT), Smith & Nephew (SNN), and GSK (GSK). MDT reported strong Q1 results and raised FY27 EPS guidance. SNN cut FY26 sales guidance. GSK plans a Phase 3 trial for its mRNA flu vaccine.

Analysts initiated coverage on five companies: Evercore ISI rated Lumentum (LITE) Outperform with $1,100 target; BTIG rated Smith & Nephew (SNN) Neutral; Morgan Stanley rated Attovia (ATTO) Overweight with $39 target; Roth Capital rated Ticketplus (TP) Buy with $14 target; Stifel rated Braveheart Bio (BRVE) Buy with $45 target.

John Rogers, CFO of Smith+Nephew (LON: SN, NYSE: SNN), will leave to become EVP and CFO at Baxter in October. Smith+Nephew reported $1.6B in Q2 revenue and reduced its full-year growth forecast to 4%. The company has initiated a search for Rogers' successor, with Pierre Palassian serving as interim CFO.

UK inflation rose to 2.9% year-on-year in July, driven by energy prices. Analysts expect further inflation due to energy and food price pressures. The FTSE 100 opened higher, led by mining stocks like Rio Tinto, Glencore, and Anglo American. Rio Tinto is reportedly in talks for a $600M investment in McEwen Copper. Shell and BP also gained, while Smith & Nephew dropped over 3% after its CFO stepped down. Geopolitical tensions in the Middle East are pushing oil prices higher. Oxford Nanopore Techn

Smith & Nephew plc announced CFO John Rogers will step down on September 30. Pierre Palassian, SVP of Finance, will serve as interim CFO. The company is searching for a permanent replacement. Smith & Nephew's shares closed 2.07% higher at GBp 1,110.50 on Tuesday.

Smith+Nephew (LSE:SN, NYSE:SNN) and Imperial College London have launched a five-year partnership to accelerate research in robotic surgery for musculoskeletal conditions. The center will focus on making robotic surgery less invasive and more accessible, with research topics including markerless tracking and real-time computer vision. The collaboration aims to bring academic breakthroughs to clinical use more rapidly, with Smith+Nephew providing resources and expertise. The center will be led by

Romania’s Nuclearelectrica (BVB: SNN) reported net profit of RON 1.18 billion for H1 2026, up 36.6% year on year, per its Bucharest Stock Exchange filing. Operating profit rose 33.7% on higher electricity sales revenues and removal of the Energy Transition Fund contribution, partly offset by higher operating costs. The Aug. 13 shutdown due to low Danube levels may reduce revenues.